Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Haycox

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|March 1, 2011
Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costsBrian Godman, Solveig Sakshaug, Christian Berg, et al.
Pharmacoeconomics|January 18, 2008
Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companiesBrian Godman, Alan Haycox, Ulrich Schwabe, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Insight into recent reforms and initiatives in Austria: implications for key stakeholdersBrian Godman, Anna Bucsics, Thomas Burkhardt, et al.
Applied Health Economics and Health Policy|January 29, 2011
Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are availableMagda Wladysiuk, Aleksander Araszkiewicz, Brian Godman, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|February 4, 2010
Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implicationsDiane McGinn, Brian Godman, Julie Lonsdale, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|April 18, 2009
Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevanceBrian Godman, Björn Wettermark, Mikael Hoffmann, et al.
Pharmacogenomics|November 3, 2017
An assessment of the impact of pharmacogenomics on health disparities: a systematic literature reviewAntony Martin, Jennifer Downing, Michelle Maden, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|November 28, 2009
Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future directionAnna Coma, Corinne Zara, Brian Godman, et al.
Pharmacoeconomics|June 20, 2008
Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in EuropeBjörn Wettermark, Brian Godman, Karolina Andersson, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Generic olanzapine: health authority opportunity or nightmare?A Aleksander Araszkiewicz, Katarzyna Szabert, Brian Godman, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Expert Review of Pharmacoeconomics & Outcomes Research|March 1, 2011
Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costsBrian Godman, Solveig Sakshaug, Christian Berg, et al.
Pharmacoeconomics|January 18, 2008
Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companiesBrian Godman, Alan Haycox, Ulrich Schwabe, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Insight into recent reforms and initiatives in Austria: implications for key stakeholdersBrian Godman, Anna Bucsics, Thomas Burkhardt, et al.
Applied Health Economics and Health Policy|January 29, 2011
Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are availableMagda Wladysiuk, Aleksander Araszkiewicz, Brian Godman, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|February 4, 2010
Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implicationsDiane McGinn, Brian Godman, Julie Lonsdale, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|April 18, 2009
Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevanceBrian Godman, Björn Wettermark, Mikael Hoffmann, et al.
Pharmacogenomics|November 3, 2017
An assessment of the impact of pharmacogenomics on health disparities: a systematic literature reviewAntony Martin, Jennifer Downing, Michelle Maden, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|November 28, 2009
Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future directionAnna Coma, Corinne Zara, Brian Godman, et al.
Pharmacoeconomics|June 20, 2008
Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in EuropeBjörn Wettermark, Brian Godman, Karolina Andersson, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Generic olanzapine: health authority opportunity or nightmare?A Aleksander Araszkiewicz, Katarzyna Szabert, Brian Godman, et al.
Pageof 5